Announcements
- FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
- Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
- Sandoz reports first quarter 2024 sales
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
- Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
- Sandoz reports fourth quarter 2023 sales and full-year 2023 results
- Sandoz receives FDA approval for first and only denosumab biosimilars
- Sandoz announces nominations to the Board of Directors and leadership change
More ▼
Key statistics
On Monday, Sandoz Group AG (D8Y:BRN) closed at 34.88, -1.47% below its 52-week high of 35.40, set on Jul 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.41 |
---|---|
High | 34.95 |
Low | 34.41 |
Bid | 33.50 |
Offer | 36.00 |
Previous close | 34.49 |
Average volume | 1.14k |
---|---|
Shares outstanding | 431.00m |
Free float | 413.07m |
P/E (TTM) | -- |
Market cap | 14.92bn CHF |
EPS (TTM) | -- |
Annual div (ADY) | 0.45 CHF |
---|---|
Annual div yield (ADY) | 1.30% |
Div ex-date | May 03 2024 |
Div pay-date | May 07 2024 |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼